Formulation and in vivo Evaluation of Chronomodulated Drug Delivery of Nimodipine
Abstract
Chronotherapy has been emerging as a novel technology in the field of pharmaceutical research. Delivery of drugs with respect to the circadian rhythm has gained greater importance in the diseases such as diabetes, asthma and hypertension in producing maximum therapeutic action. Present study focus on the formulation and evaluation of Nimodipine pulsatile release tablets with the incorporation of Eudragit pH sensitive polymers used for the chronotherapy of hypertension. Pharmacologically Nimodipine is an anti-hypertensive agent that acts by blocking the L and N-type calcium channels. Evaluation parameters for Nimodipine tablets included friability, drug content, bulk and tapped density, angle of repose and Carr’s index and drug release in vitro and in vivo.
Keywords:
Chronotherapy, circadian variation, hypertension, press coated tablets, pulsatile.DOI
https://doi.org/10.25004/IJPSDR.2019.110607References
Sajan J, Cinu TA, Chacko AJ, Litty J, Jaseeda T. Chronotherapeutics and Chronotherapeutical drug delivery system. Tro. J. Pharma Res. 2009; 8(5): 467-475.
Traynor K, Newton DW, Hrushesky JM, Reiter RJ. A Pharmacist’s Primer on Chronotherapeutics American Pharmacy. 1992; 32 (2): 261-269.
Shanmugan P, Bandameedi R. Chronotherapeutics Drug delivery system. J Drug Metab Toxicol. 2015; 2(1): 204-15.
Parmar RD, Parikh RK, Vidyasagar G, Patel DV, Patel CJ, Patel BD. Pulsatile drug delivery systems: an overview. Int J pharm sci nanotech. 2009; 2(3):605-614.
Korner A, Larsson A, Andersson A, Piculelle L. Swelling and polymer erosion for polyethylene oxide tablets of different molecular weights polydispersities. J Pharm Sci. 2009; 99:1225-1238.
Lin HL, Lin SY, Lin YK, Ho HO, Lo YW, Sheu MT.. Release characteristics and in vitro–in vivo correlation of pulsatile pattern for a pulsatile drug delivery system activated by membrane rupture via osmotic pressure and swelling. Europ J Pharm Biopharm. 2008; 70:289-301.
Mc Conville J, Ross A, Florence A, Stevens H. Erosion characteristics of an erodible tablet incorporated in time delayed capsule device. Drug Dev. Ind. Pharm. 2005; 31:35-42.
Minami J, Kawano Y, Makino Y, Matsuoka H, Takishita, S. Effects of cilnidipine, a novel dihydropyridine calcium antagonist, on autonomic function, ambulatory blood pressure and heart rate in patients with essential hypertension". British J Clin Pharmacol. 2017; 50 (6): 615–620.
Shetty R, Vivek G, Naha K, Tumkur A, Raj A, Bairy KL. Excellent Tolerance to Cilnidipine in Hypertensives with Amlodipine - Induced Edema. North American J Med Sci. 2017; 5 (1): 47–50.
Matsui Y, Eguchi K, Shibasaki S, Ishikawa J, Hoshide S, Pickering TG, Shimada K, Kario K. Effect of doxazosin on the left ventricular structure and function in morning hypertensive patients: the Japan Morning Surge 1 study. J Hypertens. 2008; 26:1463–1471.
Marfella R, Siniscalchi M, Nappo F, Gualdiero P, Esposito K, Sasso FC, Cacciapuoti F, Di Filippo C, Rossi F, D'Amico M, Giugliano D. Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. Am J Hypertens. 2005; 18:308–318.
Raghavendra K, Koland M. An In-Vivo Evaluation of Chronotherapeutical Drug Delivery System for the Treatment of Hypertension, Saudi Journal of Medical and Pharmaceutical Sciences. 2017; 3(6B):643-647.
Published
Abstract Display: 434 
PDF Downloads: 752 
